Latest News and Press Releases

Leuven, BELGIUM, Boston, MA, US – July 11, 2022 – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage...

Negma Group heeft 180 converteerbare obligaties geconverteerd resulterende in een kapitaalverhoging van EUR 450.000 en Kreos/Pontifax converteerbare obligaties werden terugbetaald ten belope van een...

Negma Group has converted 180 convertible bonds resulting in a EUR 450,000 capital increase and Kreos/Pontifax convertible bonds have been reimbursed in an amount of EUR 3 million Leuven, BELGIUM,...

Leuven, BELGIUM, Boston, MA, US – JUNE 13, 2022 – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical...

Leuven, BELGIUM, Boston, MA, US – JUNE 7, 2022 – Oxurion NV (Euronext Brussels: OXUR), a clinical stage biopharmaceutical company developing next generation standard of care ophthalmic therapies in...

Leuven, BELGIUM, Boston, MA, US – JUNE 3, 2022 – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage...

Leuven, BELGIUM, Boston, MA, US – June 1, 2022 – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage...

Negma Group heeft 200 converteerbare obligaties in Oxurion geconverteerd resulterende in een kapitaalverhoging van EUR 500.000. Deze conversie vormt deel van Negma Group’s EUR 30 miljoen...

Negma Group has converted 200 convertible bonds in Oxurion resulting in a EUR 500,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to...

   Leuven, België, Boston, MA, VS – 25 mei 2022 – 19.00u CET – Oxurion NV (Euronext Brussels: OXUR) (de “Vennootschap” of “Oxurion”), een biofarmaceutisch bedrijf dat oogheelkundige...